Last reviewed · How we verify
Combi 3 group
At a glance
| Generic name | Combi 3 group |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Low-Level Laser Auriculotherapy in the Treatment of Myogenic Temporomandibular Disorders and Anxiety (NA)
- Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers (PHASE1)
- Myoinositol Treatment and Asprosin Levels in PCOS (NA)
- Cognitive Model for Behavioral Interventions as a Personalized Intervention for Patients With Serious Mental Illness (NA)
- Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life? (NA)
- A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components (PHASE2)
- The Effect of a Liraglutide on IVF in Obese PCOS (PHASE4)
- Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combi 3 group CI brief — competitive landscape report
- Combi 3 group updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI